



PRESS RELEASE

BRAIN CEO Dr. Holger Zinke appointed to the EU Commission Bioeconomy Panel.

Zwingenberg, September 17, 2013: Dr. Holger Zinke, founder and CEO of the biotechnology company BRAIN AG, has been appointed as one of 30 members on the European panel. The members of the "European Bioeconomy Panel" were selected by the EU Commission from 250 international experts. The first constitutive conference will take place today in Brussels.

The European Bioeconomy Panel consists of key experts from the fields of science, research, politics, business, industry and public services. In addition to Dr. Holger Zinke, two more German members were appointed to the panel: Dr. Doris Schnabel from the North Rhine-Westphalian Department of Innovation, and Prof. Dr.-Ing. Peter Pickel, deputy director of the European Technology and Innovation Centre (ETIC), John Deere GmbH & Co in Kaiserslautern.

The task and objective of the five directorates AGRI - Agriculture ENTR - Enterprise and Industry, ENV - Environment, MARE - Maritime Affairs and Fisheries and the RTD - research and innovation body, is to oversee the implementation of the European Union's bioeconomy strategy,

Contact:

B•R•A•I•N
Biotechnology Research
And Information Network AG

Dr. Martin Langer
Unit Head
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-(0)-6251-9331-16
Fax.: +49-(0)-6251-9331-11
E-Mail: ml@brain-biotech.de
www.brain-biotech.de

B·R·A·I·N

to improve communication between initiatives and the political and economic sectors, both at EU and national levels, and to create synergies in European actions and measures for a bio-based economy in Europe.

In 2010, the President of the EU Commission, Prof. Dr. J.M. Barroso, published an economic strategy for the EU Commission entitled, "Europe 2020: A strategy for smart, sustainable and inclusive growth", which referred to the establishment of a sustainable, bio-based economic system as a key action ("key deliverable").

The "Bioeconomy Strategy" introduced in 2012 entitled, "Innovating for Sustainable Growth: A Bioeconomy for Europe" and its associated action plan clarifies this, and the establishment of a bioeconomy panel and a bioeconomy observatory for monitoring and supervising the effectiveness of policy measures was announced.

The bioeconomy sector is worth 2 trillion Euros in annual turnover and employs 22 million people, accounting for 9% of total employment figures, making it a key component of the European economy. It is expected that 130.000 new jobs and an added value of 45 billion Euros can be generated by 2025 through the Horizon 2020 scheme alone.

"The challenges of building a bio-based economy in terms of sustainable development are both enormous and diverse, it is a complex system. It is an honour to be able to bring the experience of a networked technology company to the 'European Bioeconomy Panel' ", says Dr. Holger Zinke. "By now, BRAIN AG has worked as a white biotechnology company on nearly 100 completed projects on the development of novel biological products and processes across the entire range of industries. The crucial element is the integration of development and

market across the entire value chain, removing obstacles to market entry and allowing access to capital.”

Dr. Zinke is also vice chairman of the Industrial Association White Biotechnology e.V. (IWBio) and a member of the German Bioeconomy Council, as a spokesman for the working group competition.

Further informations can be found under the following links:

EU Bioeconomy Panel :

<http://ec.europa.eu/research/bioeconomy/>

EU Bioeconomy Strategy:

http://ec.europa.eu/research/bioeconomy/pdf/201202_innovating_sustainable_growth.pdf

Barroso Paper “Europe 2020”:

<http://ec.europa.eu/eu2020/pdf/COMPLET%20EN%20BARROSO%20%20%20007%20-%20Europe%202020%20-%20EN%20version.pdf>

German BioÖkonomierat:

<http://biooekonomierat.de/>

German „Industrieverbund Weisse Biotechnologie“:

www.iwbio.org

B·R·A·I·N

B·R·A·I·N

About BRAIN

BRAIN AG is an industrial “white” biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to the discovery and production of new biological compounds and biocatalysts, the company achieves creative solutions by harnessing nature’s untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. Since its foundation in 1993, BRAIN has entered into over 80 strategic collaborations with nearly all the relevant companies within the chemical industry as e.g. BASF, Ciba, Clariant, Evonik, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz, Schering, Südzucker and Symrise, to name but a few. Currently, BRAIN employs 110 highly skilled people.

For their groundbreaking industrial biotechnology activities for a sustainable „biologisation of the chemical industry“ using nature’s toolbox for industrial processes, BRAIN with its CEO Dr. Holger Zinke received the “Deutschen Umweltpreis 2008” of the “Deutsche Bundesstiftung Umwelt”, DBU.

www.brain-biotech.de



Dr. Holger Zinke, CEO BRAIN AG

©Kristian Barthen, Archiv BRAIN AG

Pictures and Text can also be found in the net:

www.brain-biotech.de under „News“.